PTEN (Phosphatase and tensin homolog)

These challenges highlight an important shift-SCCE is no longer a clinical "black box" but rather a frontier that demands resolution through a translational lens. By realigning fragmented basic research with clinical evidence, this review not only presents a comprehensive picture of SCCE but also aims to provide clear therapeutic direction for this malignancy.

The combination of BAI and VPA exerted stronger inhibitory effects on cell migration and greater promotion of apoptosis compared to either agent alone, with efficacy comparable to that of the chemotherapeutic drug doxorubicin...The synergistic pro-apoptotic effect was significantly reversed upon scavenging ROS with N-acetylcysteine or by knocking down PTEN expression, confirming a positive feedback regulatory relationship between ROS and PTEN...BAI and VPA exert a synergistic anti-hepatocellular cancer effect through the ROS-PTEN-Bax pathway. This study provides a novel and effective therapeutic strategy for liver cancer and establishes a solid experimental foundation for repurposing VPA as a clinical adjuvant agent for BAI therapy.

The initial intensified systemic regimen is the doublet therapy of Darolutamide (600 mg orally twice daily) and goserelin (10.8 mg administered subcutaneously every 3 months). During 20 months of follow-up, the patient maintained an undetectable PSA, and had no radiographic evidence of disease relapse with well treatment tolerance. This case suggests that darolutamide plus ADT, administered as a tailored perioperative intensified systemic strategy, may induce a rapid and profound PSA response and may be associated with pCR in selected patients with very high-risk LAPC, while further investigation is warranted.

These findings suggest that CRISPR/Cas9-mediated modulation of miR-21 may influence tumor suppressor pathways and reduce the migratory potential of urothelial carcinoma cells.

In addition, F-AX exhibited resistance to simulated gastrointestinal digestion, suggesting its potential to reach the colon intact and exert localized colonic effects. Overall, this study highlights the potential of maize bran-derived F-AX as a nutraceutical candidate for CRC management and provides a foundation for further in vivo investigations.

RNF14 knockdown or TAF1 overexpression repressed FAO of CRC cells, which was overturned by TAF1 or PINK1 silencing, respectively. In conclusion, RBM15/YTHDF1-mediated m6A modification of RNF14 mRNA contributed to FAO enhancement via ubiquitination of TAF1 to transcriptionally inhibit PINK1, thus promoting CRC progression.

c-Myc activation, particularly MYC gene amplification, is a key driver and specific biomarker for an aggressive phenotype and poor prognosis in prostate adenocarcinoma. Combined detection of ERG, PTEN, and c-Myc status contributes to refining risk stratification systems. The lack of significant association between MYC amplification and ERG expression suggests they may represent distinct oncogenic pathways, warranting further validation in large prospective studies.

Immunohistochemistry confirmed hallmark features of EMT in the uterus of double-mutant mice, including strong downregulation of E-cadherin (CDH1) and upregulation of the EMT regulator SNAIL (Snai1). These findings demonstrate that synergistic mutations of PTEN and CTNNB1 promote early invasion, EMT activation, and metastatic progression, offering mechanistic insight into the aggressive behavior and poor clinical outcomes associated with this subtype of EEC.

Furthermore, static magnetic fields have been reported to increase apoptosis, inhibit proliferation, and may offer a complementary treatment with low toxicity. These findings suggest that magnetic-field-based approaches offer an innovative strategy for GBM treatment.

TRIM37-triggered post-translational modification of PTEN via ubiquitination may have a vital function in promoting HCC progression. These findings suggest that targeting the TRIM37/PTEN/AKT/GSK-3β/β-Catenin axis may offer a promising therapeutic approach for the management of HCC.

Future integration with multi-omics data, radiomics, and artificial intelligence (AI) promises to enhance its clinical utility. Overcoming current hurdles through standardization and technological innovation is essential for its routine clinical adoption.

These net costs amount to $0.88 per-member-per-month. While introduction of capivasertib could reduce adverse event and follow-up costs, it may result in an overall increase in payers' budget.